Literature DB >> 16732160

Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy.

Susanne M Roberts1, Alexandra F Freeman, Susan M Harrington, Steven M Holland, Patrick R Murray, Adrian M Zelazny.   

Abstract

We report 2 sisters with hyper-IgE syndrome treated with daily suppressive dosages of linezolid (LZD) who developed LZD-resistant Staphylococcus aureus carrying the G2576T mutation in the 23S rRNA gene. Molecular typing suggested transmission of the resistant strain from one sister to the other. LZD-susceptible S. aureus was isolated 2 months after LZD discontinuation. LZD-resistant S. aureus remains rare but may occur while receiving suppressive therapy.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16732160     DOI： 10.1097/01.inf.0000219401.70804.1a

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  12 in total

Review 1.  Resistance to linezolid caused by modifications at its binding site on the ribosome.

Authors:  Katherine S Long; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

Review 2.  Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia?

Authors:  Andrea Endimiani; Kristine M Hujer; Andrea M Hujer; Sebastian Kurz; Michael R Jacobs; David S Perlin; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

Review 3.  Individualising Therapy to Minimize Bacterial Multidrug Resistance.

Authors:  A J Heffernan; F B Sime; J Lipman; J A Roberts
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

4.  Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.

Authors:  Lauren M Boak; Jian Li; Craig R Rayner; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

5.  Use of linezolid in neonatal and pediatric inpatient facilities--results of a retrospective multicenter survey.

Authors:  A Simon; E Müllenborn; M Prelog; W Schenk; J Holzapfel; F Ebinger; A Klabunde-Cherwon; J Faber; A H Groll; K Masjosthusmann; C Dohna-Schwake; K Beutel; E Dirkwinkel; T Lehrnbecher; R A Ammann; A Müller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-03       Impact factor: 3.267

6.  R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance.

Authors:  Eugene Skripkin; Timothy S McConnell; Joseph DeVito; Laura Lawrence; Joseph A Ippolito; Erin M Duffy; Joyce Sutcliffe; François Franceschi
Journal:  Antimicrob Agents Chemother       Date:  2008-07-28       Impact factor: 5.191

Review 7.  Treatment strategies for methicillin-resistant Staphylococcus aureus infections in pediatrics.

Authors:  Jason G Newland; Gregory L Kearns
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

8.  Activity of linezolid in an in vitro pharmacokinetic-pharmacodynamic model using different dosages and Staphylococcus aureus and Enterococcus faecalis strains with and without a hypermutator phenotype.

Authors:  Boubakar B Ba; Corinne Arpin; Branly Bikie Bi Nso; Véronique Dubois; Marie-Claude Saux; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2010-01-25       Impact factor: 5.191

9.  The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas.

Authors:  P E Pertel; B I Eisenstein; A S Link; B Donfrid; E J A Biermann; P Bernardo; W J Martone
Journal:  Int J Clin Pract       Date:  2009-03       Impact factor: 2.503

Review 10.  The emerging problem of linezolid-resistant Staphylococcus.

Authors:  Bing Gu; Theodoros Kelesidis; Sotirios Tsiodras; Janet Hindler; Romney M Humphries
Journal:  J Antimicrob Chemother       Date:  2012-09-04       Impact factor: 5.758
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.